Skip to content

Veoza 45mg (Fezolinetant) Film-Coated Tablets – 28 or 84 Tablets

Veoza 45mg Tablets contain fezolinetant, a non-hormonal prescription medicine used to treat moderate to severe hot flushes and night sweats associated with menopause, also known as vasomotor symptoms (VMS).

Unlike hormone replacement therapy (HRT), Veoza does not contain oestrogen or progesterone. It works by blocking neurokinin 3 (NK3) receptors involved in the brain’s temperature regulation, helping reduce the frequency and severity of menopause-related hot flushes.

Veoza is taken once daily and is available in two supply quantities:

  • 28 tablets

  • 84 tablets

Price range: £99.00 through £237.00

Clear

Your Health & Wellness Centre

Trusted pharmacy advice, tips and guides for all your healthcare needs

UK Pharmacist Prescribers

Safe & compliant prescribing

GPhC-Approved

UK-Registered Pharmacy

No GP Appointments Needed

Quick, hassle-free online consultation

Secure & Confidential

Your data is 100% protected

Fast & Discreet Delivery

Next-day UK delivery available

NHS Services

NHS Providing Service since 2020

Additional information

Quantity

28 TABS, 84 TABS

Description

Veoza 45mg – Non-Hormonal Relief from Menopause Hot Flushes and Night Sweats

Veoza 45mg Film-Coated Tablets are a prescription-only, non-hormonal medicine developed to treat moderate to severe vasomotor symptoms associated with menopause.

During menopause, changes in oestrogen levels affect the body’s temperature regulation system. This can lead to sudden sensations of intense heat, flushing, sweating and night sweats, which may interrupt sleep and everyday activities.

Veoza contains fezolinetant, a neurokinin 3 (NK3) receptor antagonist. Rather than replacing declining hormone levels, it acts on specific signalling pathways in the brain involved in controlling body temperature.

By blocking NK3 receptor activity, Veoza helps reduce the frequency and severity of hot flushes and night sweats.

Veoza may provide a treatment option for women who prefer a non-hormonal approach or for whom hormone replacement therapy is unsuitable. However, it is not appropriate for everyone, and prescribing requires an assessment of medical history, liver health and potential medicine interactions.

How Does Veoza Work?

The hypothalamus is the part of the brain responsible for regulating body temperature.

During menopause, declining oestrogen levels can affect nerve cells involved in temperature control. These include KNDy neurons, which use neurokinin B signalling.

Increased activity in this pathway contributes to the narrowing of the body’s temperature regulation range, triggering hot flushes and sweating.

Veoza blocks NK3 receptors, reducing the effect of neurokinin B signalling on the body’s temperature regulation system.

This helps control menopause-related hot flushes and night sweats without directly replacing oestrogen.

What Symptoms Does Veoza Treat?

Veoza is specifically licensed to treat:

  • Moderate to severe hot flushes associated with menopause.

  • Moderate to severe night sweats associated with menopause.

By reducing night sweats, it may also improve sleep that is disrupted by these symptoms.

However, Veoza is not licensed to treat every menopause symptom. It is not a treatment for vaginal dryness, osteoporosis or other conditions caused by oestrogen deficiency.

Veoza Compared with Hormone Replacement Therapy

Feature Veoza Traditional HRT
Treatment type Non-hormonal Hormonal
Main action Blocks NK3 receptors Replaces or supplements hormones
Contains oestrogen No Often
Contains progesterone No Depends on formulation
Treats hot flushes Yes Yes
Treats night sweats Yes Yes
Treats vaginal dryness Not specifically Some HRT formulations can
Requires liver monitoring Yes, specific mandatory schedule Depends on clinical circumstances
Administration Once-daily tablet Tablets, patches, gels or sprays

Veoza is not automatically safer than HRT. Each treatment has different benefits, risks, contraindications and monitoring requirements.

Key Benefits

  • Non-hormonal treatment for menopause-related hot flushes.

  • Helps reduce the frequency and severity of night sweats.

  • Contains fezolinetant 45mg per tablet.

  • Does not contain oestrogen or progesterone.

  • Works through NK3 receptors involved in temperature regulation.

  • Convenient once-daily oral administration.

  • May improve sleep disrupted by night sweats.

  • Offers an alternative treatment approach for selected women who cannot or prefer not to use HRT.

  • Available in 28-tablet and 84-tablet supply quantities.

  • Does not require additional progesterone for womb-lining protection because it is not an oestrogen treatment.

Product Details

Detail Information
Product Name Veoza 45mg Tablets
Active Ingredient Fezolinetant
Strength 45mg per tablet
Brand Veoza
Manufacturer Astellas Pharma
Medicine Type Non-hormonal menopause treatment
Drug Class Neurokinin 3 receptor antagonist
Form Film-coated oral tablets
Pack Options 28 or 84 tablets
Main Use Moderate to severe menopausal vasomotor symptoms
Recommended Dose One 45mg tablet daily
Administration Oral
Prescription Required Yes
Liver Function Monitoring Required

Directions

Veoza must be taken exactly as prescribed by your doctor or pharmacist.

Recommended Dosage

The recommended dose is one Veoza 45mg tablet once daily.

How to Take Veoza

  1. Take one tablet every day at approximately the same time.

  2. Swallow the tablet whole with water.

  3. Veoza can be taken with or without food.

  4. Do not break, crush or chew the tablet.

  5. Continue treatment according to your prescribed schedule.

  6. Attend all required liver function blood tests.

  7. Do not take more than one tablet daily to make up for a missed dose.

What If You Miss a Dose?

If you forget to take Veoza, take the missed tablet as soon as possible unless there are fewer than 12 hours before your next scheduled dose.

If fewer than 12 hours remain, skip the missed dose and continue your usual schedule the following day.

Do not take a double dose.

How Long Does Each Pack Last?

Pack quantity Daily dose Duration
28 tablets One tablet 28 days
84 tablets One tablet 84 days

Liver Function Monitoring Requirements

Because Veoza has been associated with serious drug-induced liver injury, liver function monitoring is essential.

Monitoring stage Requirement
Before treatment Liver function blood tests
First month Repeat liver function tests
Second month Repeat liver function tests
Third month Repeat liver function tests
After three months Further tests based on clinical judgement
If liver symptoms develop Immediate medical assessment and liver function testing

Treatment must not be started if ALT or AST levels are at least twice the upper limit of normal, or if total bilirubin is significantly elevated as specified in the prescribing information.

Your prescriber will assess your results and determine whether treatment can be started or continued.

Ingredients

Active Ingredient

Each film-coated tablet contains:

Fezolinetant 45mg.

Other Ingredients

Tablet core:

  • Mannitol (E421).

  • Hydroxypropyl cellulose (E463).

  • Low-substituted hydroxypropyl cellulose (E463a).

  • Microcrystalline cellulose (E460).

  • Magnesium stearate (E470b).

Film coating:

  • Hypromellose (E464).

  • Talc (E553b).

  • Macrogol (E1521).

  • Titanium dioxide (E171).

  • Red iron oxide (E172).

These ingredients are listed in the UK Summary of Product Characteristics.

Side Effects

Like all medicines, Veoza can cause side effects, although not everyone experiences them.

Common Side Effects

The following have been reported in clinical studies:

  • Diarrhoea.

  • Difficulty sleeping (insomnia).

  • Abdominal pain.

  • Increased liver enzymes (ALT or AST) detected through blood tests.

Diarrhoea and insomnia were among the most frequently reported adverse reactions.

Serious Side Effects – Liver Injury

Veoza has been associated with serious cases of drug-induced liver injury, including cases reported after the medicine became available.

Stop taking Veoza and seek immediate medical advice if you develop:

  • Yellowing of the skin or whites of the eyes (jaundice).

  • Dark urine.

  • Pale-coloured stools.

  • Unusual or persistent tiredness.

  • Severe or persistent itching.

  • Nausea or vomiting.

  • Loss of appetite.

  • Abdominal pain.

These symptoms may indicate liver injury and require urgent assessment.

Some patients develop abnormal liver function tests without noticeable symptoms, which is why regular blood tests are required.

Warnings

Do Not Take Veoza If You:

  • Are allergic to fezolinetant or any other ingredient.

  • Are taking medicines that moderately or strongly inhibit the CYP1A2 enzyme.

  • Are pregnant or think you may be pregnant.

Speak to Your Doctor Before Taking Veoza If You:

  • Have liver disease or a history of liver problems.

  • Have abnormal liver function blood test results.

  • Have severe kidney problems.

  • Have a history of breast cancer or another oestrogen-dependent cancer.

  • Are currently receiving treatment for an oestrogen-dependent cancer.

  • Have a history of seizures or convulsive disorders.

  • Are taking hormone replacement therapy containing oestrogen.

  • Take other prescription medicines, over-the-counter products or herbal supplements.

Important Medicine Interactions

Veoza must not be used with moderate or strong CYP1A2 inhibitors because they can substantially increase fezolinetant exposure.

Examples include:

  • Fluvoxamine.

  • Mexiletine.

  • Enoxacin.

  • Certain contraceptives containing ethinylestradiol.

Your prescriber or pharmacist must review your complete medication list before treatment.

Other Important Precautions

Liver disease: Veoza should be avoided in patients with known liver disease or a higher risk of liver injury. It is not recommended for moderate or severe chronic hepatic impairment.

Kidney disease: Veoza is not recommended for severe kidney impairment or end-stage renal disease.

Breast cancer: Safety has not been established in women undergoing treatment for breast cancer or other oestrogen-dependent malignancies. Veoza is not recommended during such treatment.

HRT: Using Veoza alongside systemic oestrogen HRT has not been adequately studied and is not recommended.

Pregnancy: Veoza must not be used during pregnancy. Women who could become pregnant should discuss effective contraception with their prescriber.

Breastfeeding: Veoza is not indicated during breastfeeding.

Older patients: There is insufficient evidence to establish a dosing recommendation for women starting Veoza after 65 years of age.

Storage

  • Veoza does not require any special storage conditions.

  • Keep tablets in their original packaging.

  • Keep out of the sight and reach of children.

  • Do not use after the expiry date printed on the packaging.

  • Do not use tablets if the blister packaging is damaged.

  • Return unused or expired medicine to a pharmacy for safe disposal.

Reviews

There are no reviews yet.

Be the first to review “Veoza 45mg (Fezolinetant) Film-Coated Tablets – 28 or 84 Tablets”

Your email address will not be published. Required fields are marked *

Verified customer reviews